Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Biomea Fusion Inc (BMEA)

Biomea Fusion Inc (BMEA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,005
  • Shares Outstanding, K 37,572
  • Annual Sales, $ 0 K
  • Annual Income, $ -138,430 K
  • EBIT $ -133 M
  • EBITDA $ -131 M
  • 60-Month Beta -0.23
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.50

Options Overview Details

View History
  • Implied Volatility 161.92% ( +37.98%)
  • Historical Volatility 213.14%
  • IV Percentile 71%
  • IV Rank 13.41%
  • IV High 747.02% on 04/14/25
  • IV Low 71.34% on 08/08/24
  • Put/Call Vol Ratio 1.16
  • Today's Volume 1,185
  • Volume Avg (30-Day) 2,089
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 38,647
  • Open Int (30-Day) 23,720

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -0.64
  • Number of Estimates 4
  • High Estimate -0.50
  • Low Estimate -0.79
  • Prior Year -1.03
  • Growth Rate Est. (year over year) +37.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2905 +40.26%
on 05/28/25
3.0800 -41.23%
on 06/17/25
+0.2400 (+15.29%)
since 05/20/25
3-Month
1.2905 +40.26%
on 05/28/25
3.0800 -41.23%
on 06/17/25
-0.9600 (-34.66%)
since 03/20/25
52-Week
1.2905 +40.26%
on 05/28/25
13.0700 -86.15%
on 10/09/24
-3.3800 (-65.13%)
since 06/20/24

Most Recent Stories

More News
Biomea Fusion Reports Preclinical Data for BMF-650, a Next-Generation Oral GLP-1 Receptor Agonist Candidate, Demonstrating Robust Weight Loss and Appetite Suppression in Obese Non-Human Primates

BMEA : 1.8100 (-5.24%)
Biomea Fusion Announces Pricing of Public Offering of Securities

BMEA : 1.8100 (-5.24%)
Biomea Fusion Announces Proposed Public Offering of Securities

BMEA : 1.8100 (-5.24%)
Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

BMEA : 1.8100 (-5.24%)
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:OTLK),(NASDAQ:EYEN),(NYSE:BLCO),(NASDAQ:BMEA) EQNX::TICKER_END

OTLK : 1.7050 (+1.49%)
AVAI : 0.5400 (-14.15%)
BMEA : 1.8100 (-5.24%)
AMD : 128.24 (+1.14%)
BLCO : 11.73 (+1.56%)
EYEN : 4.21 (-12.84%)
Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue Opportunities

OTLK : 1.7050 (+1.49%)
AVAI : 0.5400 (-14.15%)
BMEA : 1.8100 (-5.24%)
BLCO : 11.73 (+1.56%)
EYEN : 4.21 (-12.84%)
Biomea Fusion’s BMF-500 Selected for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

BMEA : 1.8100 (-5.24%)
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights

BMEA : 1.8100 (-5.24%)
IVEY PMI Reading Due Next Week in Canada

IVEY PMI Reading Due Next Week in Canada U.S. Monday Economic Lookahead Consumer credit ...

WDFC : 234.84 (-3.56%)
TLRY.TO : 0.51 (-1.92%)
JPM : 275.00 (+0.38%)
AGF-B.TO : 12.63 (+1.85%)
MAMA : 7.90 (-0.75%)
CCA.TO : 68.48 (+0.15%)
BYRN : 30.33 (-2.00%)
RPM : 106.82 (-0.19%)
DAL : 47.20 (-0.76%)
LEVI : 17.59 (-0.11%)
SMPL : 32.29 (-1.52%)
PLAY : 32.77 (+2.21%)
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BMEA : 1.8100 (-5.24%)

Business Summary

Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.

See More

Key Turning Points

3rd Resistance Point 2.0700
2nd Resistance Point 2.0100
1st Resistance Point 1.9100
Last Price 1.8100
1st Support Level 1.7500
2nd Support Level 1.6900
3rd Support Level 1.5900

See More

52-Week High 13.0700
Fibonacci 61.8% 8.5702
Fibonacci 50% 7.1802
Fibonacci 38.2% 5.7903
Last Price 1.8100
52-Week Low 1.2905

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar